Prof. Dr. med. Peter Fasching



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry (2026) Hörner M, Hartkopf A, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, et al. Journal article A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence (2026) Khor CC, Ong WS, Lim EH, Chatelut E, Chen S, Muerdter TE, Abraham JE, et al. Journal article Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma (2026) Zwimpfer TA, Fereday S, Pandey A, Ariyaratne D, Jayawardana MW, Twomey L, Laumont CM, et al. Journal article SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer (2026) Bidard FC, Barrios C, Bianchini G, Brufsky AM, Chia S, Cortes J, Cristofanilli M, et al. Journal article AGO Breast Panel Recommendations for the use of treatment-relevant biomarkers in early and advanced breast cancer—2026 Update (2026) Hartkopf A, Albert US, Bartsch R, Bauerfeind I, Banys-Paluchowski M, Bjelic-Radisic V, Blohmer JU, et al. Journal article, Review article Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort (2026) Denkert C, Rachakonda S, Pehl A, Marmé F, Martin M, Karn T, Untch M, et al. Journal article Breast cancer prevention in patients with gBRCA-mutated ovarian cancer (2026) Amann N, Krückel A, Brückner L, Gocke J, Müller C, Heindl F, Hack C, et al. Journal article Interception of molecular relapse in breast cancer: The SURVIVE HERoes study (NCT06643585). (2026) Janni W, Friedl TW, Huesmann ST, Rack B, Heublein S, Schäffler H, Mehmeti F, et al. Journal article Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial (2026) Hörner M, Tretschock LM, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, et al. Journal article Interactions between genetic and epidemiological factors influencing mammographic density (2026) Suger AH, Chen H, Haas CB, Fan S, Scott CG, Bolla MK, Dennis J, et al. Journal article